ShigOraVax is a collaborative project funded by the European & Developing Countries Clinical Trials Partnership (EDCTP2) Programme supported by the European Union. The project is the joint effort of leading Asian, African and European experts with proven track records in research and development of vaccines against poverty-related neglected diseases, including diarrhoeal diseases.
at a Glance
The ShigOraVax project aims at advancing the clinical development of a safe, efficacious and affordable Shigella vaccine. We will develop oral Shigella vaccine called ‘ShigOraVax’ against three serotypes of Shigella flexneri (2a, 3a, and 6) as well as Shigella sonnei.
Specific objectives of this project include (i) conduct of a phase Ia/b clinical trial in European and African adults followed by (ii) an age de-escalating phase II in Burkina Faso and a multi-centre phase IIb clinical trial in Burkina Faso and Zambia. Moreover, specific epidemiologic data will be generated on the incidence of Shigella disease in the two African countries among children under five. The results of this project will strengthen the vaccine pipeline against a major diarrhoeal disease and making it available for late stage clinical development.
This project is part of the EDCTP2 Programme supported by the European Union (RIA2018V-2308)